BX211

AXP000218.1 · Phage therapy

Platform
personalised phage therapy (PhageBank)
Originator
Adaptive Phage Therapeutics
Sponsor
BiomX

Names

NameTypeSource
BX211preferred name, codecurator, press

Virus

Role
Phage
Family
Caudoviricetes
Virus
Staphylococcus aureus bacteriophage (patient-matched from a phage bank)
Replication
replicating
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Notes

Personalised anti-Staphylococcus aureus phage treatment for diabetic foot osteomyelitis, matched to the patient's isolate from the PhageBank collection. Developed by Adaptive Phage Therapeutics, which BiomX acquired in March 2024; the phase 2 DANCE trial NCT05177107 (APT.DFI.001) is the trial BiomX reported as positive BX211 topline data in March 2025, so BX211 and the APT DFO product are one program, not two. Route not taken from a primary source yet, so left empty. PhageBank itself is a platform (SPEC section 1), not a program.

How to cite

BX211 (AXP000218.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000218.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.